Form 4: Kymera CMO Sells Shares After Option Exercise

Kymera Therapeutics' Chief Medical Officer, Jared Gollob, sold 49,307 shares of common stock on December 8, 2025, following the exercise of stock options.

Summary

• Jared Gollob, Chief Medical Officer of Kymera Therapeutics, Inc. (KYMR), executed transactions on December 8, 2025.
• Exercised options to acquire 49,307 shares of common stock at an exercise price of $5.33 per share.
• Simultaneously sold all 49,307 shares of common stock in multiple transactions at weighted average prices ranging from $87.3711 to $92.19.
• These transactions were conducted under a Rule 10b5-1 trading plan established on June 2, 2025.
• Following these transactions, Mr. Gollob directly beneficially owns 109,992 shares of common stock and 34,083 derivative securities (stock options).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, even though it was pre-planned. While 10b5-1 plans mitigate the negative signal, a reduction in insider ownership can still be viewed with caution by some investors.

Positives

• The exercise of stock options at a low price of $5.33 per share indicates a significant unrealized gain for the officer.
• The transactions were pre-planned under a Rule 10b5-1 trading plan, suggesting a structured approach to managing personal holdings rather than an immediate reaction to company news.

Negatives

• The sale of 49,307 shares by a Chief Medical Officer could be perceived negatively by some investors, as it reduces insider ownership.

Risks

• Potential negative investor sentiment due to insider selling, which could put downward pressure on the stock price.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This Form 4 filing reflects a routine insider transaction for liquidity or portfolio diversification, common in the biotechnology industry for executives with significant equity compensation. It does not inherently indicate a shift in broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal, potentially leading to minor short-term price fluctuations, although the pre-planned nature mitigates significant negative impact.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the execution of the trading plan.

Key Dates

Recommendation

While the insider selling by the Chief Medical Officer might raise some questions, the transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to new negative company information. Without additional company-specific news or broader market context, this single insider transaction does not warrant a change from a 'hold' position.

Keywords

Kymera Therapeutics, KYMR, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Jared Gollob, Chief Medical Officer, Rule 10b5-1